Trial reportTransfusion2014
Transfusion-associated hepatitis before the screening of blood for hepatitis risk factors.
Trial report in Transfusion, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan.PloS one · 2018Trial
- Role of viral and host factors in determining the outcome of HBV-associated acute liver failure.Journal of translational medicine · 2026Article
- The Use of Residual Blood Specimens in Seroprevalence Studies for Vaccine-Preventable Diseases: A Scoping Review.Vaccines · 2025Review
- Prevalence of Hepatitis B and Hepatitis C in Patients undergoing hemodialysis at a teaching hospital in Uttarakhand.Journal of family medicine and primary care · 2022Article
- Article
- Distinct disease features in chimpanzees infected with a precore HBV mutant associated with acute liver failure in humans.PLoS pathogens · 2020Article
- Hepatitis E: What We Think We Know.Clinical liver disease · 2020Review
- Prevalence and molecular characterization of occult hepatitis B virus in pregnant women from Gondar, Ethiopia.Canadian liver journal · 2020Article
- Probable transmission of hepatitis E virus (HEV) via transfusion in the United States.Transfusion · 2019Article
- Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study.BMC public health · 2018Article
- Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma.Molecular cancer research : MCR · 2018Article
- Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.PloS one · 2017Article
- Molecular biology of hepatitis B virus infection.Virology · 2015Review
- Clinicoepidemiology and Diagnosis of Hepatitis C: Evaluating HCV Core Antigen Assay as a Diagnostic Tool in a Tertiary Care Teaching Hospital of North India.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe true incidence of transfusion-associated hepatitis (TAH) before blood screening is unknown. Our aims were to reevaluate blood recipients receiving unscreened blood and analyze hepatitis viruses circulating more than 45 years ago. STUDY DESIGN AND
methodsCryopreserved serum samples from 66 patients undergoing open heart surgery in the 1960s were reevaluated with modern diagnostic tests to determine the incidence of TAH and its virologic causes.
resultsIn this heavily transfused population receiving a mean of 20 units per patient of predominantly paid-donor blood, 30 of 66 (45%) developed biochemical evidence of hepatitis; of these, 20 (67%) were infected with hepatitis C virus (HCV) alone, four (13%) with hepatitis B virus (HBV) alone, and six (20%) with both viruses. Among the 36 patients who did not develop hepatitis, four (11%) were newly infected with HCV alone, nine (25%) with HBV alone, and one (3%) with both viruses. Overall, 100% of patients with hepatitis and 39% of those without hepatitis were infected with HBV and/or HCV; one patient was also infected with hepatitis E virus. The donor carrier rate for HBV and/or HCV was estimated to be more than 6%; contemporaneously prepared pooled normal human plasma was also contaminated with multiple hepatitis viruses.
conclusionTAH virus infections were a larger problem than perceived 50 years ago and HCV was the predominant agent transmitted. All hepatitis cases could be attributed to HCV and/or HBV and hence there was no evidence to suggest that an additional hepatitis agent existed undetected in the blood supply.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.